Forecast to Publish a Notice of Funding Opportunity (NOFO) for NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed)

<p>This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.</p><p>NCORP will support the following components that will be individually awarded through the respective RFAs indicated below:</p><ul><li>NCORP Research Bases (UG1 Clinical Trials Required);</li><li>NCORP Community Sites (UG1 Clinical Trials Not Allowed); and</li><li>NCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)</li></ul><p><br></p><p><strong><em>NCORP Community Sites</em></strong>&nbsp;are consortia of community hospitals and/or oncology practices, which may or may not be formally affiliated in a healthcare system, that accrues participants to cancer control, prevention, treatment and care delivery clinical trials and other human subjects research.</p><p>NCORP Community Sites are expected to meet or exceed the required annual 70 new unique patient/participant accruals evenly distributed between cancer control, prevention, and screening/post-treatment surveillance trials, and treatment and imaging trials, respectively. Participation in cancer care delivery studies will be optional. For those who propose cancer care delivery participation, NCORP Community Sites must meet or exceed the required minimum of 3 cancer care delivery protocols open per year. NCORP Community Sites interact with the NCORP Research Bases by: 1) providing insight into clinical significance during concept development; 2) identifying care disparities in their local populations that could be studied; and 3) providing input on feasibility during protocol development.</p>